Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Get Free Report) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totaling 3,321 shares, a drop of 87.9% from the August 31st total of 27,525 shares. Based on an average daily volume of 8,922 shares, the short-interest ratio is currently 0.4 days. Approximately 0.3% of the shares of the stock are short sold.
Virtus LifeSci Biotech Products ETF Price Performance
Virtus LifeSci Biotech Products ETF stock traded down $0.06 on Friday, reaching $104.57. The company’s stock had a trading volume of 5,367 shares, compared to its average volume of 8,708. The business’s fifty day moving average price is $102.66 and its 200 day moving average price is $92.95. Virtus LifeSci Biotech Products ETF has a twelve month low of $68.05 and a twelve month high of $110.05.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Virtus LifeSci Biotech Products ETF stock. Comprehensive Financial Planning Inc. PA acquired a new position in shares of Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,971 shares of the company’s stock, valued at approximately $557,000. Comprehensive Financial Planning Inc. PA owned about 1.27% of Virtus LifeSci Biotech Products ETF as of its most recent SEC filing.
About Virtus LifeSci Biotech Products ETF
The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is managed by Virtus.
Recommended Stories
- Five stocks we like better than Virtus LifeSci Biotech Products ETF
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Virtus LifeSci Biotech Products ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virtus LifeSci Biotech Products ETF and related companies with MarketBeat.com's FREE daily email newsletter.
